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The accurate prediction of cardiovascular (CV) risk has been
one of the ultimate tasks of contemporary preventive CV
medicine. Presently, the clinician’s arsenal contains valuable
tools for risk prediction, such as the Framingham risk score,
the Systemic Coronary Risk Evaluation (SCORE), and
other scoring systems, which are based on established risk
factors. However, even with those scoring systems, risk
prediction is often an elusive goal because considerable
differences between predicted and actual event rates may
occur. Thus, current research is targeting clinically relevant
novel biomarkers that can improve our ability to predict CV
risk when added to existing risk scoring systems.
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Before implementation of novel biomarkers in clinical
practice, enthusiasm of researchers should be tampered, and
a critical approach must prevail. A biomarker deserves
clinical integration only if the following criteria (1) are met:
1) it must differ between subjects with and without
outcomes; 2) it must predict future outcomes in prospective
studies; 3) it must add predictive information on top of
established risk markers; 4) it must reclassify patients’ pre-
dicted risk to a sufﬁcient extent; 5) its use must improve
outcomes when evaluated in a randomized study; and 6) it
must be cost efﬁcient.
Aortic stiffness, and speciﬁcally aortic pulse wave velocity
(aPWV), has been increasingly recognized as a valuable
biomarker for CV risk prediction. Indeed, aPWV has
strong pathophysiological links with the mechanisms ofublished in the Journal of the American College of Cardiology reﬂect the
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nary blood ﬂow (2,3). In contrast to variables such as blood
pressure, levels of lipids or glucose, and so on, which reﬂect
the instantaneous (at the time of measurement) intensity of
classical risk factors but ﬂuctuate considerably over time,
aPWV integrates and reﬂects the long-term effect of the
established, as well of the currently unknown, risk factors on
the arterial wall, together with the genetic predisposition of
the individual. It can be measured with reliable and repro-
ducible noninvasive techniques (2–4), now that, of para-
mount importance for implementation in clinical practice,
normal values validated in large populations are available (5).
Numerous longitudinal studies have so far shown the
independent relationship between aPWV and CV events in
diverse populations. In 2010, we published in the Journal
a summary data meta-analysis (6) including all reported
longitudinal studies. We showed that aPWV signiﬁcantly
predicts risk and quantiﬁed this predictive ability. When we
updated that analysis by including 10 new studies (7–16)
fulﬁlling the criteria of our meta-analysis (6) among 27
new longitudinal studies until September 2013, results
remained practically unchanged (Fig. 1, top panel). In this
issue of the Journal, Ben-Shlomo et al. (17) conﬁrm our
ﬁndings by a meta-analysis of individual patient data from
16 studies. More speciﬁcally, after adjusting for age and
sex, the increase in risk for CV events, CV mortality, and
total mortality was 45%, 41%, and 22%, respectively, for
an increase of 1 SD change in log aPWV, whereas after
adjusting for additional risk factors, the respective increases
were 30%, 28%, and 17%. In a practical interpretation of
the results, for a 60-year-old man who is a nonsmoker,
nondiabetic, normotensive, and normolipidemic, a 1 m/s
increase in aPWV leads to a 7% increase of the hazard for
CV events.
Importantly, the study of Ben-Shlomo et al. (17) takes
the issue of risk prediction with aPWV a decisive step
further. Existing evidence is convincing that aPWV fulﬁlls
biomarker criteria 1, 2, and 3 (2,3,6,7–17), described in the
preceding text. However, to prove its predictive value,
a biomarker should further demonstrate that a clinically
meaningful proportion of individuals beneﬁt by changing
their risk status, or in other words, they are correctly
reclassiﬁed to higher or lower risk categories when this
biomarker is measured. Although the ability of several CV
biomarkers, including aPWV, to predict CV risk has been
debated (18,19), the present study (17) provides compelling
evidence that the addition of aPWV improves the overall
10-year risk classiﬁcation for intermediate-risk subjects (i.e.,
those in particular need for potential reclassiﬁcation) by an
important percentage (13%). Thus, criterion 4 is also met.
This updated evidence on the predictive ability of aPWV
should have an impact on clinical practice recommendations.
The 2010 guidelines of the American College of Car-
diology/American Heart Association for assessment of CV
risk in asymptomatic adults (20) recommended against
the measurement of aPWV for CV risk assessment in
Figure 1
RR and 95% CI for a 1-SD Increase in
aPWV and Clinical Events
Relative risks (RRs) and 95% conﬁdence intervals (CIs) for a 1-SD increase in
aortic pulse wave velocity (aPWV) and total cardiovascular (CV) events, CV
mortality, and all-cause mortality according to summary data meta-analysis
(updated analysis of Vlachopoulos et al. [6] including 10 new studies [that
reported risk for a 1-SD increase in aPWV in a literature search until September
2013] to a total of 27 studies, top panel) and individual data meta-analysis
(Ben-Shlomo et al. [17], 16 studies, bottom panel). The diamonds and their width
represent the pooled RRs and the 95% CIs, respectively.
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648asymptomatic adults, mainly on the basis of the lack of
evidence (at the time of their publication) supporting the
ability of aPWV to reclassify risk in asymptomatic adults/
general population. The present study (17) provides valuable
proof into this ﬁeld and calls for a critical reconsideration
of the role of aPWV as a predictive tool in subjects free of
CV disease in such guidelines. The current European view,
on the other hand, is in line with available evidence. The
recent 2013 European Society of Hypertension/European
Society of Cardiology guidelines for the management of
arterial hypertension (21) recommend measurement of
aPWV for evaluation of subclinical organ damage in
hypertensive patients (recommendation Class IIa, Level of
Evidence: B), and suggest a cutoff of 10 m/s to discriminate
between normal aortic elasticity and aortic stiffening (4).
Is there still room for improvement? Criterion 5, the
potential role of aPWV as an independent treatment target,
should be met beyond early studies (22). The ongoing
SPARTE (Statégie de Prévention Cardiovasculaire Basée
sur la Rigidité Arterielle) study (23), together with other
studies, will shed light on this important parameter. Cost
effectiveness (criterion 6) has not been precisely addressed.However, cost is currently moderate and is further decrea-
sing as application is wide spreading. This is an important
advantage compared with other powerful, but costly, bio-
markers such as the coronary artery calcium score. It should
also be added to other important advantages, such as the
noninvasive nature of measurement that poses no risk, and
the ease of use for both the performer and the patient that
facilitate implementation in clinical practice.
aPWV has gone a long way and has come to an age of
maturity. Given the evidence we now have, and after critical
consideration, aPWV is justiﬁed to be included in clinical
practice for risk prediction. So, just measure it! Just do it!
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